tiprankstipranks
Trending News
More News >

FibroGen Announces Strategic Sale and Financial Outlook

FibroGen Announces Strategic Sale and Financial Outlook

FibroGen ( (FGEN) ) has released its Q4 earnings. Here is a breakdown of the information FibroGen presented to its investors.

Confident Investing Starts Here:

FibroGen, Inc. is a biopharmaceutical company focused on developing novel therapies in cancer biology and anemia, with notable products like roxadustat for anemia in chronic kidney disease and FG-3246 for prostate cancer treatment. In its latest earnings report, FibroGen announced the sale of FibroGen China to AstraZeneca for approximately $160 million, which is expected to extend the company’s cash runway into 2027. The company also highlighted the initiation of a Phase 2 trial for FG-3246, a promising antibody-drug conjugate for prostate cancer, expected by mid-2025. Financially, FibroGen reported a decrease in total revenue from $46.8 million in 2023 to $29.6 million in 2024, with a significant reduction in net loss from $323.0 million in 2023 to $153.1 million in 2024. The company remains optimistic about its future, focusing on strategic milestones and maintaining a strong financial position post-sale of its Chinese operations.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1